Smartlens Raises $5.2 Million to Advance FDA Clearance of Electronics-Free Contact Lens for Continuous Glaucoma Monitoring
核心洞察
Smartlens (搜索) secured $5.2 million in oversubscribed bridge funding led by Ambit Health Ventures (搜索) to advance FDA clearance and prepare for commercial launch of its miLens (搜索) technology.
The miLens (搜索) represents the world's first electronics-free soft contact lens capable of continuously monitoring intraocular pressure (搜索), a key risk factor in glaucoma (搜索) progression.
The device integrates with an AI-powered smartphone imaging platform to analyze pressure fluctuations throughout the day, enabling data-driven treatment optimization for ophthalmologists.
Smartlens (搜索), Inc., a clinical-stage ophthalmic technology company, has closed an oversubscribed $5.2 million bridge funding round to advance the FDA clearance process for its revolutionary glaucoma (搜索) monitoring technology. The financing, led by Ambit Health Ventures (搜索), will support the company's preparation for expedited market launch of its miLens (搜索) product following regulatory approval.
The round included continued participation from existing investors Graphene Ventures (搜索) and Boutique Venture Partners (搜索), along with new investment from Harvard Business School Alumni Angels GNY (搜索) and a group of eyecare providers.
Breakthrough Contact Lens Technology
miLens (搜索) represents a significant advancement in ophthalmic innovation as the world's first electronics-free soft contact lens capable of continuously monitoring intraocular pressure (搜索) (IOP). The device's microfluidic design allows for continuous monitoring in real-world environments, eliminating the limitations of traditional in-office IOP measurements that provide only intermittent snapshots of eye pressure.
Working with Smartlens (搜索)' AI-powered smartphone imaging platform, miLens (搜索) captures critical pressure fluctuations throughout the day and enables data-driven treatment optimization. The technology analyzes pressure variations to provide ophthalmologists with comprehensive insights for patients with glaucoma (搜索), ocular hypertension (搜索), or those requiring post-surgical pressure monitoring.
Addressing Critical Medical Need
Glaucoma (搜索) and ocular hypertension (搜索) affect over 150 million people globally and remain the leading cause of irreversible blindness. Elevated intraocular pressure (搜索) is the only modifiable risk factor for disease progression, yet existing diagnostic approaches rely on infrequent, single-point measurements. Smartlens (搜索) aims to bridge this gap through continuous, real-world monitoring, enabling earlier intervention and more effective therapy adjustments.
"We're laying the foundation for the next generation of glaucoma (搜索) management—one driven by continuous, data-based insight rather than intermittent snapshots," said Savas Komban, CEO and co-founder of Smartlens (搜索), Inc. "The continued confidence from our investors underscores both the scale of the opportunity ahead and the meaningful impact miLens (搜索) can have for patients worldwide."
Clinical Progress and Regulatory Advancement
The company has made substantial advancements in regulatory preparation, manufacturing scale-up, and clinical validation, citing strong clinical progress in its multi-site U.S. pivotal trial. The ongoing clinical trial aims to validate the safety and effectiveness of miLens (搜索) for everyday use.
Alongside clinical validation, Smartlens (搜索) has made significant strides in manufacturing readiness and regulatory preparation to ensure rapid scalability following FDA clearance. The company plans to use the new capital to finalize regulatory submissions, expand its operational and manufacturing infrastructure, and lay the groundwork for commercial rollout once FDA clearance is obtained.
Industry Support and Future Outlook
"Smartlens (搜索) continues to make impressive progress with its technology, and miLens (搜索) is a true leap forward in ophthalmic innovation," added Sam Goldberger, MD, MBA, co-founder and managing partner of Ambit Health Ventures (搜索). "We are proud to lead this strategic round as the company advances through the FDA clearance process, positioning Smartlens not just for commercial launch, but to redefine continuous glaucoma (搜索) monitoring and transform patient care worldwide."
The successful bridge round strengthens Smartlens (搜索)' position for future growth and further development of its platform for additional ophthalmic applications beyond glaucoma (搜索). The company plans to initiate commercial activities following FDA clearance, with strong clinical interest already demonstrated in the miLens (搜索) technology.